Phathom Pharmaceuticals is a biopharmaceutical company.
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.Phathom has assembled a leading team of seasoned gastrointestinal and pharmaceutical industry experts with proven experience developing and commercializing highly innovative therapies.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 1, 2022 | Post-IPO Debt | $40M | 2 | — | — | Detail |
Sep 20, 2021 | Post-IPO Debt | $200M | 1 | Hercules Capital | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Hercules Capital | — | Post-IPO Debt |
Sagard Healthcare Royalty Partners | — | Post-IPO Debt |